The research analyzed data from six breast cancer databases, including The Cancer Genome Atlas and determined that RIP2 was significantly overexpressed in TNBC and correlated with worse progression-free survival.
cancer patients, in which it is over expressed.
It's another target, folks. And another target might mean a targeted drug.
I do think RIP is an ominous name, but I guess they weren't looking at that.
You can read the entire study here.